https://idataresearch.com/wp-content/themes/lambda-child-theme/images/footer-logo.png
https://idataresearch.com/wp-content/themes/lambda-child-theme/images/idata-white-logo.png

Diabetes

Diabetes Devices Market Reports

The diabetes medical device market encompasses many different categories and sub-categories, and the disease continues to be a major problem. Even though uncertainties continue to plague the healthcare system in the U.S., the market should continue to trend upward in the coming years.

iData Research produces diabetes devices market reports that are unmatched in their depth and accuracy, providing healthcare companies of all sizes the necessary intelligence to help them determine their most effective strategies.

Showing the single result

Diabetes Monitoring, Treatment and Drug Delivery Procedure Volume Analysis | United States | 2017-2023 | MedPro

The full report suite on the U.S. market for diabetes monitoring, treatment and drug delivery includes blood glucose meters, blood glucose test strips, lancets and lancing devices, continuous glucose monitoring (CGM), insulin, inulin pens, insulin syringes and insulin pumps. Sanofi and Novo Nordisk recently launched next-generation insulin products: insulin glargine U-300 (Toujeo®) and insulin degludec (Tresiba®), respectively. Both of these insulin analogs are “ultra-long-acting” and have an average duration of 24 to 36 hours, which means that patients will only be required to perform once-daily injections. Novo Nordisk is currently developing Ryzodeg®, a premixed insulin analog comprising insulin degludec (Tresiba®) and insulin aspart (NovoLog®), in addition to an “ultra-rapid-acting” insulin analog, which are both expected to be launched during the forecast period. The insulin-dependent patient population is expected to transition to next-generation insulin products and will contribute to the growth of the insulin market and associated insulin delivery markets.

more...